Published on September 25th, 2019 | by CRST0
CRST and Avilex Pharma have announced collaboration in development of Avilex drug candidate AVLX-144
Avilex Pharma and CRST have initiated cooperation to prepare Avilex Pharma compound AVLX-144 for the clinical development in ischemic stroke which is one of the most frequent causes of death in the Western world and the primary cause of long-term disability such as paralysis and loss of function.
CRST’s CEO, Antti Iiitä comments: “We are really happy that specialists working for Avilex Pharma chose to collaborate with CRST in early clinical development based on our experience and scientific knowledge. We are very much looking forward to work with this interesting compound. Our aim is always to help our customers to gather as much information about their assets as early as possible and we are very much looking forward to do that also with Avilex Pharma.”
“We look forward to work with CRST’s team in this interesting development program during trial planning phase and also during the actual clinical conduct. The two teams have worked well together to facilitate the development plan for AVLX-144. ” comments Kristian Strømgaard, Chief Executive Officer of Avilex Pharma.
Ville Ranta-Panula, M.Sc, MBA
Chief Commercial Officer